

Systematic Review

Efficacy of Laser Therapy in Trigeminal Neuralgia; A Systematic Review

Sara Haghighat¹, DMD Student; Fahimeh Rezaadeh², DMD, MScD; Hossein Sedarat³, MD Student; Amir Tabesh⁴, DMD Student; Elham Tayebi Khorami⁴, DMD Student; Kiana Aghasadeghi⁵, DMD Student;

¹ Student Research Committee, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.

² Oral and Dental Disease Research Center, Dept. of Oral and Maxillofacial Medicine, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.

³ Undergraduate Medical Student, Student Research Committee, Jahrom University of Medical Sciences, Jahrom, Iran.

⁴ Undergraduate Student, Student Research Committee, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.

⁵ Undergraduate Student, Student Research Committee, School of Dentistry, Azad University, Shiraz, Iran.

KEY WORDS

Trigeminal neuralgia;
Laser therapy;
Review systematic;
Facial pain;

Received:

Revised:

Accepted:

ABSTRACT

Statement of the Problem: Trigeminal neuralgia is the most common and disabling type of neuralgia in craniofacial region. Because of adverse effects of first and second lines of treatment, new modalities including laser therapy have been investigated for treatment of trigeminal neuralgia.

Purpose: The aim of this study was to review the effect of laser in trigeminal neuralgia. PubMed, Scopus, Web of Science, Science Direct and Embase databases from December 1983 to August 2020 were searched using keywords “trigeminal neuralgia” and “laser”. Our inclusion criteria were interventional studies with a randomized clinical trial design, which used laser for treatment of trigeminal neuralgia.

Materials and Method: A total of 269 records were identified through systematically searching aforementioned databases among which, 30 were from PubMed and 44 were from Web of Science. A total of 111 records were duplicated and were therefore removed.

Results: Only 17 records were considered relevant after reading title and abstracts. After reading full texts of the articles, 13 met the eligibility criteria and were included in our review.

Conclusion: This review revealed that low-level laser therapy reduces pain in trigeminal neuralgia specially diode lasers, although there are no standardized protocols for laser procedures.

Corresponding Author: Tabesh A, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran. Tel: +98-9377730668 Email: amirtabesh@sums.ac.ir

Cite this article as:

Introduction

Neuralgias are amongst the most painful situations that are experienced by human [1]. Trigeminal neuralgia (TN) is the most common and disabling type of neuralgia in craniofacial region [2-3] which is characterized by paroxysmal attacks of shock-like stabbing, penetrating, sharp pain that mostly happens unilateral in skin of eyebrows, eyes, lips, nose, scalp, forehead, jaw and peri-ocular structures [1,4]. The duration of pain episodes can vary in each patient but they occur and terminate suddenly and are mostly less than two minutes [3,5]. There is usually at least one trigger point in affected

patients and innocuous stimuli such as brushing, eating, talking, and even washing the face may cause onset of the pain [5-6].

Different numbers have been reported as the prevalence of TN such as 1 in 25,000 [7], 4 out of 100000 [8], 1 in 15000 individuals [5], and 0.05% [9] but the actual prevalence might be significantly higher due to undiagnosed or misdiagnosed cases. Mostly females and middle-aged individuals older than 50 years old are involved with this disease [3,7,10]. The female to male ratio of TN is reported to be 3 to 1 [10].

There are different theories that explain the possible

causes of paroxysmal pain in neuralgia pain episodes including external pressure of artery on trigeminal nerve root (neurovascular decompression), focal demyelination of trigeminal nerve afferents and hyper excitability of axons, brain stem infarction, cerebellopontine angle tumors and abnormality in expression of voltage-gated sodium channels [3,8,10-11]. However, the exact underlying mechanism of TN is not completely understood and is remained unclear yet.

The diagnosis and management of TN is particularly complicated and require a multi-disciplinary approach including neurology, neurosurgery, oral and maxillofacial surgery, and oral medicine specialists [7]. Although there are some tools for diagnosis of TN including laser evoked potentials (LEP) and magnetic resonance imaging (MRI) [12-13], none of them can provide a definitive diagnosis and still, a precise interview with the patient is the best method for ruling out other differential diagnoses [8].

There are different strategies for treatment of TN. Drug therapy by anti-epileptic drugs is the first line of treatment. Carbamazepine is the drug of choice according to several evidences [6-7,10,14-15]. However, drug therapy is approximately non-satisfying in 20-50% of cases [5,10] and its efficacy decreases over time [15]. Carbamazepine also has side effects like headache, dizziness, decrease in postural stability and alertness, nausea, erythema multiform, and decrease in white blood cell count that turns into aplastic anemia in severe cases [5, 9, 16-17] that further limits its use.

Surgery is another more invasive treatment modality, which is indicated in more complicated refractory cases. There are several methods of surgery including stereostatic radiosurgery [3, 6, 18], ganglion block surgery [11], percutaneous radiofrequency thermal rhizotomy [7], and microvascular decompression [19]. Surgery is not acceptable by all patients and it should be postponed concerning its invasive nature and side effects. Paresthesia, dysesthesia, numbness of facial skin, and high rate of pain recurrence are among the most common side effects [11,20] but cerebrospinal fluid (CSF) leak, infarction, hematoma, aseptic meningitis, and hearing loss has been also reported as more complicated side effects [6].

Because of above adverse effects of first and second lines of treatment, new modalities have been investigat-

ed for treatment of TN including laser therapy and acupuncture [8, 16, 21-22, 27]. Low level laser therapy (LLLT) has been used in treatment of different diseases especially chronic pains and has been reported as an effective method for alleviating pain [8, 23-24]. Its mechanism of pain reducing action is through decreasing histamine, bradykinin, acetylcholine and prostaglandin E2 and increase in expression of endorphin mRNA precursor, ATP, and enkephalins [8, 11, 16].

Although few studies have evaluated laser therapy in treatment of TN, these studies reported controversial results and had different methodology; hence, in this systematic review we aim to review the effect of laser in treatment of TN.

Search sources

We searched for articles, which evaluated the effect of laser on treatment of TN. In 26 August 2020, PubMed, Scopus, Web of Science, Science Direct and Embase databases were searched using keywords “trigeminal neuralgia” and “laser” in title and abstracts parts using advanced search.

Search strategies

Our search strategy was based on a PICO question as follows: “Does using laser improve treatment of trigeminal neuralgia?” our search strategy included two parts: laser and TN which were grouped by Boolean operator “AND”. Simple Keywords were selected in order to include all possible results.

Selection of studies

Our inclusion criteria were interventional studies from December 1983 to August 2020 with a randomized clinical trial design, which used laser for treatment of TN. Studies in languages other than English and animal model studies were excluded from our results.

Data collection

Reviewers independently evaluated studies and collected data about patients (total number of TN patients and demographic information of both case and control groups), characteristics of intervention (laser type, laser wavelength, sessions of laser therapy, time / dose of exposure), comparison (placebo, surgical methods or other methods for treatment of TN), follow up (duration of follow up) and outcome characteristics (assessment tool, values in case and control groups).

Analysis of risk of bias in included studies

Two reviewers independently assessed risk of bias in all

included studies according to the Cochrane Collaboration's tool for assessing risk of bias (chapter 8.5 of the Cochrane Handbook for Systematic Reviews of Interventions, 2011).

Analysis of data

Data is reported descriptively since the results were not eligible for quantitative analysis (Meta-analysis) according to statistics specialist consult.

Selection of studies

A total of 269 records were identified through systematically searching aforementioned databases among which, 30 were from PubMed and 44 were from Web of Science. A total of 111 records were duplicated and were therefore removed. Only 17 records were considered relevant after reading title and abstracts. The main reasons for exclusion of studies were irrelevant methodology, types other than journal articles (such as conference abstracts, books, and so on) and articles in languages other than English. After reading full texts of the articles, 13 met the eligibility criteria and were included in our review. Running meta-analysis was not feasible regarding our statistics specialist consult. The process of selecting studies is shown in Figures 1 and 2.




Figure 1: Flowchart of study

Included studies characteristics

The characteristics of included studies are summarized in Table 1. Two studies compared the effect of carbamazepine with and without laser therapy in treatment of TN patients [8, 16, 25, 26]. One of the studies evaluated the adjunctive effect of laser therapy in patients undergoing ganglion block surgery [11]. In another studies, different types of laser wavelengths were compared [27, 28]. The other articles compared laser therapy as the only treatment with sham laser in groups [29, 30, 32, 33]. Only one study was compared laser with trans cranial electromagnetic (TES) [31]. In most of studies, response to treatment were evaluated by visual analogue scale (VAS) except for Walker study which used pain




Figure 2: PRISMA 2009 Flow Diagram of study

Table 1: The result of all reviewed article

	Laser type	Laser wavelength	Sessions of laser therapy	Comparison (Control group)	Number of TN patients (Case/ control)	Result assessment	Duration of Follow up	Time / dose of exposure	Result
Walker [33] 1983	He-Ne	632nm	30 (3 per week, 10 weeks)	Sham laser	12 (9/3)	### PES +5-HIAA (24 hour urine sample)	After 20 sessions of therapy	20 seconds/1mW (30 seconds increase in each week)	85 % estimated pain relief
Hensen <i>et al.</i> [29] 1990	IR	904 nm	8 (2 per week, 4 weeks)	Inactive placebo laser probe	1 was primary TN+3 secondary TN Patients	# VAS+5-HIAA (24 hour urine sample)	2,4,6 months	60 seconds/ Maximum dose of 4.7 J/cm2	NOT significant
Aghamohammadi <i>et al.</i> [35] 2012	IR	890 nm	12 (every other day)	Sham laser (Ganglion block in both groups)*	42 (21/21)	VAS	Days: 1,3,5,7 Months: 1,3,6	3-10 J per point	NOT significant
Amanat <i>et al.</i> [16] 2013	GaAs	980 nm	10 (3 per week)	Sham laser (carbamazepine in both groups)	26(12/14)	VAS	2,4 months	5 minutes on each tender point/12.73 J/cm2	NOT significant
Antonic <i>et al.</i> [27] 2017	GaAlAs	810 nm	20 (5 per week, 4 weeks)	Two wavelength	20 (10/10)	VAS **	Immediately after treatment	10 minutes / 30 mW, 3.0 J/cm2 ***	Significant (post vs pre) (810 nm vs 660 nm)
Ebrahimi <i>et al.</i> [8] 2018	GaAlAs	810 nm	9 (3 per week, 3 weeks)	Sham laser (carbamazepine in both groups)	30 (15/15)	VAS	1 month	25 seconds / 5J energy, max power 200 mW	significant
Ibrahim Saeda <i>et al.</i> [24] 2013	HeNe laser	830 nm	24 (3 per week, 8 weeks)	Laser/transcranial electromagnetic stimulation(10Hz)	30 (15/15) multiple sclerosis patients with TN	# NRS (0,5,10)	Immediately after treatment	Intra oral: 1-2 mins Extra oral: 10 mins/15 mW, density 150-170 mw/cm ²	significant
Eckerdal <i>et al.</i> [25] 1996	GaAlAs	830 nm	5 (1 per week, 5 weeks)	Sham laser (analgesics consumption in both groups)	30 (14/16)	VAS	Immediately after treatment, after 1 year	32mW,laser density of 9.2 J/ cm ²	Significant
Pinheiro <i>et al.</i> [28] 1998	IR 30 multilaser	830,632.8, 670 nm	14 (2 per week, 6 weeks and 2 sessions after one month)	3 wavelength	53	NRS	Immediately after treatment, 1 month later	40 mW, laser density of 3.9 (830 nm) to 0.2 (632.8 nm) to 0.8 (670 nm)	significant
Somchai Sessirisombat [30] 2017	CO2 laser		1 session with CO2 laser	Group who refuse surgery and non-tolerable to drugs	36	NRS	1 week,1monts, 3months, 6 months and 1 year	30seconds / Power 5 W	significant
Kim <i>et al.</i> [51] 2003	He-Ne, Ga-Al-As and CO2 lasers	904nm for Ga-Al-As 632nm for He-Ne	6	Laser group/ laser with carbamazepine	25	VAS		20mW for He- Ne and 40mW for Ga-Al-As 4 J/cm ² ,100 Hz	significant
Intsar S. Waked <i>et al.</i> [32] 2015	He-Ne		24 (3 per week, 8 weeks)	3 groups, 2 groups with 2 methods of laser application, 1 group with placebo laser probe	45(15,15,15)	NRS	Immediately after treatment	15 minute	significant
Wichuda Kongsong <i>et al.</i> [26] 2020	CO2 laser		1 session	1 group, all use carbamazepine before and after	50	NRS	1week,1month,every 3-6 months	30seconds / Power 5 W	significant

*: all patients were diagnosed with refractory TN and were using carbamazepine at baseline. **: Data of VAS were presented as median and (5th-95th) percentile boundaries. ***: not considered as one of 6 final included studies. ****: The treatment time (t) for each application point was calculated using the following equation: $t(\text{sec}) = 3.0 \frac{1}{\text{cm}^2} \times 1 \frac{\text{cm}^2}{0.003} (\text{W})$
 # NRS: Numeric Rating Scale / ## VAS: visual analogue scale / ### PES: pain effect scale

effect scale (PES) and 5-HIAA concentration which is an indicator of pain measured in urine samples [29].

Others were assessed pain by numerical rating scale (NRS) [26, 28, 30-31].

Table 2: Risk of bias of eligible studies

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessors (detection bias)	Incomplete outcome data addressed (attrition bias)	Selective outcome reporting (reporting bias)	Other bias
Walker [33] 1983	No randomization	Unclear	Low	Low	Low	Low	Sampling bias
Hensen <i>et al.</i> [29] 1990	Low	Unclear	Low	Low	Low	Low	Unclear
Aghamohammadi <i>et al.</i> [35] 2012	Low	Low	Unclear	Unclear	Low	Low	Unclear
Amanat <i>et al.</i> [16] 2013	Low	Low	Low	Low	Low	Low	Unclear
Antonic <i>et al.</i> [27] 2017	Unclear	Unclear	Unclear	Unclear	Unclear	High	Unclear
Ebrahimi <i>et al.</i> [8] 2018	Low	Low	Unclear	Unclear	Low	High	Unclear
Ibrahim Saeda <i>et al.</i> [24] 2013	Low	Unclear	Low	Low	Low	Low	Unclear
Eckerdal <i>et al.</i> [25] 1996	Low	Low	Unclear	Unclear	Low	Low	Unclear
Pinheiro <i>et al.</i> [28] 1998	Low	Low	Low	Low	Low	Low	Unclear
Somchai Sessirisombat [30] 2017	Unclear	Unclear	Low	Low	Unclear	High	Unclear
Kim <i>et al.</i> [51] 2003	Low	Unclear	Low	Low	Low	Low	Unclear
Intsar S. Waked <i>et al.</i> [32] 2015	Low	Low	Unclear	Unclear	Low	High	Unclear
Wichuda Kongsong <i>et al.</i> [26] 2020	Low	Low	Unclear	Unclear	Low	Low	Unclear

Most (nine) of the studies have reported significant improvement in pain relief after using laser as treatment of TN [25-28, 30,32]. Walker reported 85% pain relief in their study [39]. Only three studies have reported that there was no significant improvement in pain of TN patients after laser therapy [11, 16].

Assessment of risk of bias

The information about risk of bias of each article is summarized in Table 2. Only two articles was low risk in all domains [16, 28] and the others had unclear risk of bias in at least one of the domains. In attrition bias domain, all the studies were low risk except two [27, 30]. Only one study mentioned other possible sources of bias [33] although some studies had high risk concerning reporting bias [32].

Discussion

Although most assessed studies have demonstrated significant pain reduction of chronic orofacial pain by LLLT [8, 24, 27, 34], some others did not report significant pain relief after laser therapy [16, 35]. In this systematic review, we assessed the effect of laser therapy

in treatment of primary TN. After searching was completed, only three studies were found that compared laser with placebo (in order to eliminate the placebo effect) for TN pain control [29-32]. Other studies compared laser with other modalities such as medicine, surgery, ganglion block, TES, or compared two different wavelengths of laser with each other [8, 11, 27, 36]. Furthermore, some studies used laser for secondary TN or multiple sclerosis patients [29]. Based on statistician opinion, meta-analysis was not indicated due to non-uniform (equivalent) data of studies. Therefore, we only reviewed 13 similar articles based on effect of laser on TN pain reduction.

A total of 9 of 13 reviewed articles reported a significant pain decrease in TN [8, 27]. Walker also reported 85% pain relief after laser therapy [36], although others pointed no significant difference between laser and sham laser group [8, 11, 16]. Comparison the result of different studies is difficult due to variety in patient selection, number of follow up sessions, dose of laser therapy (power or time), and type of laser (wavelengths). However, in all of these articles, pain reduc-

tion, whether significant or not, may be related to psychological effects (placebo effect) [29]. In most of reviewed studies, LLLT was used except two studies that employed CO₂ laser [26, 30].

Low-level lasers have super luminous diodes and a mixture of infrared and red photons in the shape of laser. The patient feels no pain and this kind of treatment is not invasive at all. These lasers are low power in comparison with high-power ones such as surgical lasers. While the laser beam is released, the level of adenosine triphosphate in cells grows higher by light absorption of cytochrome c oxidase in the mitochondria [37].

In previous researches, LLLT has been used for the treatment of nerve problems. These studies have shown increased nerve function and improved capacity for myelin production [38, 39]. Induction of analgesic effects has been shown by LLLT. Pain relief is the result of the increase in serotonin and endorphin levels in combination with the decrease in prostaglandin E₂ and bradykinin levels. The reduction in pro-inflammatory factors (cytokines) such as tumor necrosis factor alpha (TNF α), interleukin (IL)-1 β , and the enlargement in amount of anti-inflammatory cytokines such as IL-10, quickly alleviates the inflammation [37].

In an animal study, researchers showed laser stimulated axonal growth in injured nerves and it increased the change of PGG₂ and PGH₂ into PGI₂ (prostaglandin) that act in vasodilation and anti-inflammatory action [38, 40]. The other mechanism of pain reduction in LLLT is blocking pain transmission in the peripheral nervous system by generating varicose veins which results in a reduction in fast axonal flow speed [41]. Moreover, the change in pain threshold and stimulating the neurogenesis has been suggested [42]. Therefore, LLLT by all of these mechanisms can result in pain control in TN patients.

It is substantial to choose the most appropriate wavelength while using laser therapy for each certain disease. Wavelength of laser directly determines the degree of penetration through the tissues. A wavelength of 830nm, capable of reaching the cortical and alveolar bone tissues, is considered to have the deepest penetration and yet more effectiveness than wavelengths between 620 and 670 nm [43]. Red and infrared lasers are efficient for different conditions. Red laser is indicated for superficial injuries regarding its weak penetration

and therefore greater absorption while passing through the tissues [44]. Infrared laser, on the other hand, is indicated for causing instant and impermanent analgesic effects, following from its deeper penetration through biological membranes. It interacts with the polarity alterations and induces analgesia by causing hyperpolarization on cell membrane (light-cell biological interaction) which is known to be a photo-physical mechanism [41]. Among the included studies, 4 of 5 used diode laser such as Ga-Al-As or Ga-As [8, 11, 16, 27], that showed effective for decreasing pain. Nonetheless, the diode laser with wavelength of 660-980 nm was used widely for treatment of TN and usually provided good results; it seems that this type of laser might be better for pain control of TN [5].

It should be mentioned that definitive diagnosis of TN is the most important part of treatment plan, because other chronic orofacial pain sources may interfere with TN treatment results [45].

Regarding the traits of the studies, it is highly of note that, although the studies point out the results shortly after the beginning of laser therapy, there is no agreement about the protocol of laser application.

With regard to the number of laser application, studies applied 9 up to 30 days of treatment. Moreover, frequency of sessions usually varied between 2-3 times per week. Although, one study used laser in continuous days for patients [27]. The interval sessions for laser therapy result in decreasing the cumulative effect of laser in tissue, which induce the inhibitory effect or may exacerbate the pain.

The parameters between the studies are of great variety and differ concerning recommended dose and time of application. Due to the lack of coordination between the mentioned parameters, and also the duration and number of the sessions, it is difficult to approve a certain protocol for pain control in TN.

One of the common challenges in laser therapy is the variation of the treatment dose (power density) between the studies. In our review, the applied dose was ranged between 3 up to 12j/cm². Based on Arndt-Schulz curve (rule) for LLLT, optimal dose should be in range of 0.001-10 j/cm² for stimulating physiologic process and higher dose result in inhibitory effect [46]. However, some stated that for pain control, we need inhibitory effect [47].

In our review, the risk of bias analysis in most of the studies was low; however, the obtained information from some domains of evaluation was insufficient.

Articles with language other than English were excluded from our review because they were not reachable. Furthermore, case reports also were not included to our study.

Excluding the previously mentioned articles can be pointed at as a possible limitation of this review study. However, because of English being considered the language of science, it has been claimed that the exclusion of non-English articles does not seemingly bias systematic reviews [53]. Regarding the databases, we attempted to reduce the incident of bias as much as possible, by involving articles from other sources as well, including gray literature, on account of inadequate amount of studies. It is unfortunate to note that, this research was not able to add any new articles to this review.

Thus, to conduct a sophisticated future research, various parameters of laser therapy and favorable results of previous studies must be in order to establish an irradiation protocol for TN management. Besides, it should be considered that some outcomes are patient-dependent; especially the financial aspect of this therapy in order to compare the cost-effectiveness of this procedure with the conventional therapy.

Conclusion

This review study showed that laser therapy, especially diode laser (LLLT), might be beneficial in managing TN patients. Despite the fact that there is no standard method for laser treatment, sufficient data to solve this issue is yet to be discovered and placebo effect may influence the pain reduction.

Acknowledgments

The authors thank the vice-chancellery of Shiraz University of Medical Science for supporting this research. This article is based on the thesis by Sara Haghighat from Shiraz Dental School (Grant# 17960).

Conflict of Interest

None declared.

References

[1] De Tommaso M. Laser-evoked potentials in primary hea-

daches and cranial neuralgias. *Expert Rev Neurother.* 2008; 8: 1339-1345.

[2] Squintani G, Turri M, Donato F, Tinazzi M, Masotto B, Tramontano V, et al. Trigeminal laser-evoked potentials: A neurophysiological tool to detect post-surgical outcome in trigeminovascular contact neuralgia. *Eur J Pain (United Kingdom).* 2015; 19: 253-259.

[3] Yadav YR, Nishtha Y, Sonjjay P, Vijay P, Shailendra R, Yatin K. Trigeminal Neuralgia. *Asian J Neurosurg.* 2017; 12: 585-597.

[4] de Tommaso M, Vecchio E. Primary headaches and trigeminal neuralgia: neuropathic pain yes or not? Evidences from neurophysiological procedures. *Expert Rev Neurother.* 2013; 13: 1031-1039.

[5] Falaki F, Nejat AH, Dalirsani Z. The Effect of Low-level Laser Therapy on Trigeminal Neuralgia: A Review of Literature. *J Dent Res Dent Clin Dent Prospects.* 2014; 8: 1-5.

[6] Wilhour D, Nahas SJ. The Neuralgias. *Curr Neurol Neurosci Rep.* 2018; 18: 69.

[7] Khan M, Nishi SE, Hassan SN, Islam MA, Gan SH. Trigeminal Neuralgia, Glossopharyngeal Neuralgia, and Myofascial Pain Dysfunction Syndrome: An Update. *Pain Res Manag.* 2017; 2017: 7438326.

[8] Ebrahimi H, Najafi S, Khayamzadeh M, Zahedi A, Mahdavi A. Therapeutic and analgesic efficacy of laser in conjunction with pharmaceutical therapy for trigeminal neuralgia. *J Lasers Med Sci.* 2018; 9: 63-68.

[9] Cruccu G. Trigeminal Neuralgia. *Pain Res Manag.* 2017; 23: 396-420.

[10] Di Stefano G, Truini A, Cruccu G. Current and Innovative Pharmacological Options to Treat Typical and Atypical Trigeminal Neuralgia. *Drugs.* 2018; 78: 1433-1442.

[11] Aghamohammadi D, Amirnaseri R, Peirovifar A, Hossainzadeh H, Eidi M, Ehsaei M, et al. Gasserian ganglion block with or without low-intensity laser therapy in trigeminal neuralgia: A comparative study. *Neurosurg.* 2012; 22: 228-232.

[12] Galeotti F, Truini A, Cruccu G. Neurophysiological assessment of craniofacial pain. *J Headache Pain.* 2006; 7: 61-69.

[13] Durak K, Chen ACN, Arendt-Nielsen L. 3D topographic study of the diode laser evoked potentials (LEPs) to painful stimulation of the trigeminal sensory area. *Brain Topogr.* 2004; 16: 133-138.

[14] Swedish Council on Health Technology A. SBU system-

- atic review summaries. Methods of treating chronic pain: A Systematic Review. Stockholm: Swedish Council on Health Technology Assessment (SBU) Copyright (c) 2006 by the Swedish Council on Health Technology Assessment.; Health Technol. 2006.
- [15] Marmura MJ, Kumpinsky AS. Refining the Benefit/Risk Profile of Anti-Epileptic Drugs in Headache Disorders. *CNS Drugs*. 2018; 32: 735-746.
- [16] Amanat D, Ebrahimi H, Lavaee F, Alipour A. The adjunct therapeutic effect of lasers with medication in the management of orofacial pain: Double blind randomized controlled trial. *Photomed Laser Surg*. 2013; 31: 474-479.
- [17] Spina A, Mortini P, Alemanno F, Houdayer E, Iannaccone S. Trigeminal Neuralgia: Toward a Multimodal Approach. *World Neurosurg*. 2017; 103: 220-230.
- [18] Maarbjerg S, Di Stefano G, Bendtsen L, Cruccu G. Trigeminal neuralgia - diagnosis and treatment. *Cephalalgia*. 2017; 37: 648-657.
- [19] Zakrzewska JM. Differential diagnosis of facial pain and guidelines for management. *Br J Anaesth*. 2013; 111: 95-104.
- [20] Sun G, Tunér J. Low-level laser therapy in dentistry. *Dent Clin N Am*. 2004; 48: 1061-1076.
- [21] de Oliveira RF, Goldman RS, Mendes FM, de Freitas PM. Influence of Electroacupuncture and Laser-Acupuncture on Treating Paresthesia in Patients Submitted to Combined Orthognathic Surgery and Genioplasty. *Med Acupunct*. 2017; 29: 290-299.
- [22] Costa JM, Corral-Baqués MI, Amat A. Acupuncture: a first approach on pain relief using a 617 nm led device. Mechanisms for Low-Light Therapy II. San Jose, CA; 2007. Available at: <https://ui.adsabs.harvard.edu/abs/2007SPIE.6428E..0AC/abstract>
- [23] Yang HW, Huang YF. Treatment of Persistent Idiopathic Facial Pain (PIFP) with a Low-Level Energy Diode Laser. *Photomed Laser Surg*. 2011; 29: 707-710.
- [24] Ibrahim Seada Y, Nofel R, Mahmoud Sayed H. Comparison between trans-cranial electromagnetic stimulation and low-level laser on modulation of trigeminal neuralgia. *J Phys Ther Sci*. 2013; 25: 911-914.
- [25] Eckerdal A, Bastian L. Can low reactive-level laser therapy be used in the treatment of neurogenic facial pain? A double-blind, placebo controlled investigation of patients with trigeminal neuralgia. *Laser Ther*. 1996; 8: 247-251.
- [26] Kongsong W, Sessirisombat S. Treatment outcomes of carbon dioxide laser for trigeminal neuralgia. *J Dent Lasers*. 2020; 4: 61-66.
- [27] Antonić R, Brumini M, Vidović I, Urek MM, Glažar I, Pezelj-Ribarić S. The effects of low level laser therapy on the management of chronic idiopathic orofacial pain: Trigeminal neuralgia, temporomandibular disorders and burning mouth syndrome. *Med. Flum*. 2017; 53: 61-67.
- [28] Pinheiro AL, Cavalcanti ET, Pinheiro TI, Alves MJ, Miranda ER, DE Quevedo AS, et al. Low-level laser therapy is an important tool to treat disorders of the maxillofacial region. *J Clin Laser Med Surg*. 1998; 16: 223-226.
- [29] Hansen HJ, Thoroe U. Low power laser biostimulation of chronic oro-facial pain. A double-blind placebo controlled cross-over study in 40 patients. *Pain*. 1990; 43: 169-179.
- [30] Sessirisombat S. Carbon-dioxide laser in the treatment of trigeminal neuralgia: a preliminary study. *J Interdiscipl Med Dent Sci*. 2017; 5: 208.
- [31] Seada YI, Nofel R, Sayed HM. Comparison between trans-cranial electromagnetic stimulation and low-level laser on modulation of trigeminal neuralgia. *J Phys Ther Sci*. 2013; 25: 911-914.
- [32] Waked I, Attalla A, Eid M. Low level laser therapy for the treatment of trigeminal neuralgia after oral surgeries: two different applications. *Int J Health Rehab Sci*. 2015; 4: 10-18.
- [33] Walker J. Relief from chronic pain by low power laser irradiation. *Neurosci Lett*. 1983; 43: 339-944.
- [34] Gomes RNS, Gomes VTS, Nicolau RA. Treatment of postherpetic neuralgia with low-level laser irradiation: literature review. *Sci Med*. 2016; 26: 10.
- [35] Aghamohammadi D, Eidi M, Lotfi A, Hosseinzadeh H, Movasaghi R, Motighini N, et al. Effect of low level laser application at the end of surgery to reduce pain after tonsillectomy in adults. *J Lasers Med Sci*. 2013; 4: 79.
- [36] Walker J, Akhanjee L, Cooney M, Goldstein J, Tamzyoshi S, Segal-Gidan F. Laser therapy for pain of trigeminal neuralgia. *Clin J Pain*. 1987; 3: 183-188.
- [37] Merrick RV, Kahn F, Saraga F. Treatment of postherpetic neuralgia with low level laser therapy. *Pract Pain Manag*. 2013; 13: 1-9.
- [38] Vernon LF, Hasbun R. Low-level laser therapy for trigeminal neuralgia. *Pract Pain Manag*. 2008: 56-63.
- [39] Wang CZ, Chen YJ, Wang YH, Yeh ML, Huang MH, Ho ML, et al. Low-level laser irradiation improves func-

- tional recovery and nerve regeneration in sciatic nerve crush rat injury model. PLoS One. 2014; 9: e103348.
- [40] Rezazadeh F, Hajian K, Shahidi S, Piroozi S. Comparison of the Effects of Transcutaneous Electrical Nerve Stimulation and Low-Level Laser Therapy on Drug-Resistant Temporomandibular Disorders. J Dent. 2017; 18: 187.
- [41] Deana NF, Zaror C, Sandoval P, Alves N. Effectiveness of Low-Level Laser Therapy in Reducing Orthodontic Pain: A Systematic Review and Meta-Analysis. Pain Res Management. 2017; 2017: 8560652.
- [42] Magri LV, Carvalho VA, Rodrigues FC, Bataglion C, Leite-Panissi CR. Effectiveness of low-level laser therapy on pain intensity, pressure pain threshold, and SF-MPQ indexes of women with myofascial pain. Lasers Med Sci. 2017; 32: 419-428.
- [43] Calderhead RG, Kim WS, Ohshiro T, Trelles MA, Vasily DB. Adjunctive 830 nm light-emitting diode therapy can improve the results following aesthetic procedures. Laser Ther. 2015; 24: 277-289.
- [44] Ash C, Dubec M, Donne K, Bashford T. Effect of wavelength and beam width on penetration in light-tissue interaction using computational methods. Lasers Med Sci. 2017; 32: 1909-1918.
- [45] Zakrzewska JM. Diagnosis and differential diagnosis of trigeminal neuralgia. Clin J Pain. 2002; 18: 14-21.
- [46] Huang YY, Sharma SK, Carroll J, Hamblin MR. Biphasic dose response in low level light therapy - an update. Dose Response. 2011; 9: 602-618.
- [47] Coluzzi DJ, Convissar RA. Lasers in clinical dentistry. Dent Clin N Am. 2004; 48: xi-xii.
- [48] Cruccu G, Galeotti F, Iannetti GD, Romaniello A, Truini A, Manfredi M. Trigeminal neuralgia: Update on reflex and evoked potential studies. Mov Disord. 2002; 17: S37-S40.
- [49] Cruccu G, Pennisi E, Truini A, Iannetti GD, Romaniello A, Le Pera D, et al. Unmyelinated trigeminal pathways as assessed by laser stimuli in humans. Brain. 2003; 126: 2246-2256.
- [50] Zakrzewska JM, Wu J, Brathwaite TS. A systematic review of the management of trigeminal Neuralgia in patients with multiple sclerosis. World Neurosurg. 2018; 111: 291-306.
- [51] Kim JI, Park CY, Yeom JY, Kim EB, Yoon TH. Frequency-stabilized high-power violet laser diode with an ytterbium hollow-cathode lamp. Opt Lett. 2003; 28: 245-247.
- [52] Rezazadeh F, Dehghanian P, Jafarpour D. Laser effects on the prevention and treatment of dentinal hypersensitivity: a systematic review. J Lasers Med Sci. 2019; 10: 1-11.
- [53] Nussbaumer-Streit B, Klerings I, Dobrescu AI, Persad E, Stevens A, Garrity C, et al. Excluding non-English publications from evidence-syntheses did not change conclusions: a meta-epidemiological study. J Clin Epidemiol. 2020; 118: 42-54.